Boothe Investment Group Inc. Purchases 47,261 Shares of Pfizer Inc. $PFE

Boothe Investment Group Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 17.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 324,557 shares of the biopharmaceutical company’s stock after purchasing an additional 47,261 shares during the quarter. Pfizer makes up approximately 3.0% of Boothe Investment Group Inc.’s investment portfolio, making the stock its 13th largest holding. Boothe Investment Group Inc.’s holdings in Pfizer were worth $7,867,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter worth about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the second quarter worth about $29,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.5%

Pfizer stock opened at $24.79 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.17. The stock’s 50 day simple moving average is $24.87 and its two-hundred day simple moving average is $24.17. The firm has a market cap of $140.92 billion, a PE ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.